Related Experiment Videos
Management of hypertension in chronic heart failure
Saraswathy Manickavasagam1, Ramanna Merla, Michael M Koerner
1University of Texas Medical Branch, 301 University Boulevard 5,106 John Sealy Annex, Galveston, TX 77555-0553, USA.
Insights
Managing hypertension in chronic heart failure (CHF) patients requires careful drug selection. First-line agents with proven mortality benefits in CHF should be prioritized, while others should be avoided.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) impacts millions, leading to frequent hospitalizations and high mortality.
- Hypertension (HTN) is a major risk factor for HF, preceding it in 75% of cases.
- HF presents as either reduced left ventricular systolic function or preserved systolic function (diastolic dysfunction).
Purpose of the Study:
- To review the management of essential hypertension in patients at risk for, or with, chronic heart failure.
- To discuss the latest developments in managing both hypertension and heart failure.
Main Methods:
- Review of current therapeutic strategies for hypertension in heart failure patients.
- Analysis of drug classes with proven mortality benefits and those to be avoided.
- Consideration of differences in hypertension management based on ejection fraction.
Main Results:
- First-line agents for HTN in CHF include beta-blockers, ACE inhibitors, ARBs, aldosterone blockers, hydralazine, and nitrates.
- Alpha-receptor blockers should be avoided due to increased mortality risk in HF.
- Dihydropyridine calcium channel blockers have a neutral effect on mortality and can be used for refractory HTN.
Conclusions:
- Optimal management of hypertension in CHF involves prioritizing drugs with demonstrated mortality benefits.
- Treatment strategies for hypertension differ between HF with reduced ejection fraction and HF with preserved ejection fraction.
- Ongoing research aims to identify novel treatments benefiting both hypertension and heart failure.
Abstract:
Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each year; overall, heart failure (HF) now accounts for 7% of all deaths from cardiovascular disease. Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or systolic dysfunction and those with preserved LV systolic function or diastolic dysfunction. The management of HTN in patients with CHF is challenging. Drugs such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor blockers, hydralazine and nitrates, which have shown mortality benefit in CHF and exert antihypertensive effects, should be used as first-line agents to control HTN in CHF. In addition, antihypertensive drugs such as alpha-receptor blockers that can increase mortality in HF should be avoided. The dihydropyridine group of calcium channel blockers are good antihypertensive medications with a neutral effect on mortality in patients with CHF. These may be used in CHF patients with refractory HTN. In patients with HF with reduced ejection fraction, HTN is treated differently in comparison to patients with HF with normal ejection fraction. This article reviews the treatment of essential HTN in patients at risk for developing HF, in the presence of HF and the latest developments in treatment that might benefit both HTN and HF management.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VII: Nursing Interventions
Hypertension V: Nursing Management
Heart Failure Drugs: Diuretics